Background:
@EN Celiprolol is known to be a β-adrenergic blocker with β1, a2-blocking and β2-agonizing activity, theefore differs from other β-blockers with metabolic and hemodynamic properties. We studied the antihypertensive efficacy and the effect on
lipid
profile, blood glucose concentration and side effects of celiprolol in diabetic patients with essential hypertension.
@ES Methods :
@EN 22 hypertensive patients with type II diabetes mellitus were included, 5 patients were male and the other 17 patients were female. One female patients was lost during follow-up period and one female patient was excluded due to severe
gastrointestinal disturbance. Celiprolol 200㎎ was administered once daily, then dosage was increased up to 400㎎if diastolic blood pressure, checked afte two weks of celiprolol showed above 95 mmHg.
@ES Results
@EN The blood pressure and heart rate decreased from 167.0/100.8mmHg, 82.1/min to 155.0/94.3mmHg, 75.0/min at the end of treatment, respectively (p<0.05). Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride were changed from
204.4㎎/dl,
125.9㎎/dl, 44.0㎎/dl and 172.5㎎/dl to 207.8㎎/dl, 124.0㎎/dl, 46.6㎎/dl and 182.2㎎/dl , respectively, but without statistical significance. Blood glucose concentration also showed no significant change. During the period of the study, a few
side
effects were noted such as gastrointestinal distubasnce and mild headache.
@ES Conclusion :
@EN A new β-blocker, celiprolol showed significant antihypertensive efficacy in the treatment of essential hypertension with type II diabetic patients without harmful effect on lipid profiles, and the effect on glucose metabolism seems to need
further
investigation.
|